Calidi Biotherapeutics (CLDI) Change in Accured Expenses (2022 - 2025)
Calidi Biotherapeutics' quarterly Change in Accured Expenses came in at -$808000.0 in Q4 2025, down 42.0% year-on-year from -$1.4 million in Q4 2024, and down 406.06% quarter-over-quarter from $264000.0 in Q3 2025.
Calidi Biotherapeutics has reported Change in Accured Expenses for 4 years, with the latest figure at -$808000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 42.0% year-over-year to -$808000.0; the trailing twelve-month figure through Dec 2025 stood at -$2.0 million (down 7.5% YoY), and the FY2025 full-year result was -$2.0 million, down 7.5% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at -$808000.0, down from $264000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.0 million in Q3 2022, with the low at -$1.7 million in Q1 2025.
- Average Change in Accured Expenses over 4 years is -$49812.5, with a median of -$106160.5 recorded in 2022.
- Year-over-year, Change in Accured Expenses soared 5509.07% in 2023 and slumped 334.79% in 2025.
- Tracing CLDI's Change in Accured Expenses over 4 years: stood at -$223000.0 in 2022, then surged by 359.19% to $578000.0 in 2023, then tumbled by 198.44% to -$569000.0 in 2024, then plunged by 42.0% to -$808000.0 in 2025.
- The last three Change in Accured Expenses figures came in at -$808000.0 (Q4 2025), $264000.0 (Q3 2025), and $238000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 107.70 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | -808,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -808,000.00 |
| Dec 31, 2025 | -808,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | -1.69 Mn |
| Mar 31, 2025 | -1.69 Mn |
| Dec 31, 2024 | -569,000.00 |
| Dec 31, 2024 | -569,000.00 |
| Sep 30, 2024 | -190,000.00 |
| Sep 30, 2024 | -190,000.00 |
| Jun 30, 2024 | -707,000.00 |
| Jun 30, 2024 | -707,000.00 |
| Mar 31, 2024 | -388,000.00 |
| Mar 31, 2024 | -388,000.00 |
| Dec 31, 2023 | 578,000.00 |
| Dec 31, 2023 | 578,000.00 |
| Sep 30, 2023 | -791,000.00 |
| Sep 30, 2023 | -791,000.00 |
| Jun 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 1.25 Mn |
| Mar 31, 2023 | 236,000.00 |
| Mar 31, 2023 | 236,000.00 |
| Dec 31, 2022 | -223,000.00 |
| Dec 31, 2022 | -223,000.00 |
| Sep 30, 2022 | 2.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 22,321.00 |
| Jun 30, 2022 | 22,321.00 |
| Mar 31, 2022 | -22,321.00 |
| Mar 31, 2022 | -22,321.00 |